410,535 Shares in Sana Biotechnology, Inc. $SANA Acquired by Clearline Capital LP

Key Points

• Clearline Capital LP has acquired a new stake in Sana Biotechnology, purchasing 410,535 shares valued at approximately $690,000, representing about 0.18% of the company.
• Other hedge funds have significantly increased their positions in Sana Biotechnology, with Millennium Management LLC boosting its stake by 604.8% and Two Sigma Advisers LP raising theirs by 677.0%.
• Sana Biotechnology's stock currently has a consensus rating of "Buy" from analysts, with a target price averaging $8.00, while it recently reported earnings per share of ($0.16), beating estimates.

Clearline Capital LP purchased a new position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 410,535 shares of the company's stock, valued at approximately $690,000. Clearline Capital LP owned about 0.18% of Sana Biotechnology as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of SANA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Sana Biotechnology by 2.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 280,731 shares of the company's stock valued at $457,000 after buying an additional 6,613 shares in the last quarter. Bank of New York Mellon Corp grew its position in Sana Biotechnology by 2.1% in the 1st quarter. Bank of New York Mellon Corp now owns 344,058 shares of the company's stock valued at $578,000 after buying an additional 7,230 shares in the last quarter. Hsbc Holdings PLC grew its position in Sana Biotechnology by 26.5% in the 1st quarter. Hsbc Holdings PLC now owns 41,377 shares of the company's stock valued at $65,000 after buying an additional 8,673 shares in the last quarter. Rhumbline Advisers grew its position in Sana Biotechnology by 5.4% in the 1st quarter. Rhumbline Advisers now owns 182,134 shares of the company's stock valued at $306,000 after buying an additional 9,359 shares in the last quarter. Finally, ProShare Advisors LLC grew its position in Sana Biotechnology by 25.4% in the 4th quarter. ProShare Advisors LLC now owns 47,808 shares of the company's stock valued at $78,000 after buying an additional 9,679 shares in the last quarter. Institutional investors own 88.23% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on SANA shares. JMP Securities reissued a "market outperform" rating and issued a $5.00 price target on shares of Sana Biotechnology in a report on Tuesday, June 24th. Morgan Stanley assumed coverage on shares of Sana Biotechnology in a research report on Thursday, July 3rd. They set an "overweight" rating and a $12.00 price objective for the company. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $8.00.

Sana Biotechnology Stock Performance

Shares of NASDAQ SANA traded down $0.18 during mid-day trading on Friday, reaching $3.22. The company had a trading volume of 3,000,261 shares, compared to its average volume of 4,056,273. The stock has a fifty day moving average of $3.72 and a two-hundred day moving average of $2.71. The company has a market capitalization of $765.75 million, a price-to-earnings ratio of -3.04 and a beta of 1.88. Sana Biotechnology, Inc. has a 12-month low of $1.26 and a 12-month high of $7.30.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.04. Sell-side analysts forecast that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.